LMO2 and acute lymphoblastic leukemia: For example, the STAG2/LMO2 subtype occurs in very young T-ALL patients (≤ 2-year-old) [6, 109] and renders the cells more sensitive to PARP inhibition, but potentially nelarabine as well [109].